220602-80-2

Upstream product

• 220603-08-7 (6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-6-yl)-(4-fluoro-2-trifluoromethyl-phenyl)-methanone 
• 15802-80-9 3-tert-butyl-1H-pyrazole 
• 141179-72-8 4-fluoro-2-trifluoromethylbenzoic acid 
• 10189-78-3 6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-5-one 
• 95-54-5 1,2-diamino-benzene 
• 10177-29-4 4-chloronicotinic acid 
• 189807-21-4 2-trifluoromethyl-4-fluorobenzoyl chloride 
• 16287-36-8 6,11-dihydro-5H-pyrido{2,3-b][1,5]benzodiazepine 
• 2942-59-8 2-chloronicotinic acid 

Relevant academic research and scientific papers

Pyridobenzodiazepines: A novel class of orally active, vasopressin V 2 receptor selective agonists

Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.

TRICYCLIC VASOPRESSIN AGONISTS

The present invention provides compounds of general formula (I): wherein W is O or NH, optionally substituted, as well as methods and pharmaceutical compositions utilising these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

Tricyclic pyridine N-oxides vasopressin agonists

The present invention provides compounds of the general formula: as well as methods and pharmaceutical compositions utilizing these compounds for the inducement of temporary delay of urination or the treatment of disorders which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders.